<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Drospirenone and estradiol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Drospirenone and estradiol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Drospirenone and estradiol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11528" href="/d/html/11528.html" rel="external">see "Drospirenone and estradiol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708709"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Endometrial cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Perform adequate diagnostic measures, including directed or random endometrial sampling when indicated, to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular disease:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The Women’s Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg) alone, relative to placebo. Do not use estrogen-alone therapy for the prevention of cardiovascular disease.</p>
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen plus progestin substudy reported an increased risk of pulmonary embolism, DVT, stroke, and myocardial infarction in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CEs (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo. Do not use estrogen plus progestogen therapy for the prevention of cardiovascular disease.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Breast cancer:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The WHI estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dementia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The Women’s Health Initiative Memory Study (WHIMS) estrogen-alone ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 5.2 years of treatment with daily CE (0.625 mg) alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Do not use estrogen-alone therapy for the prevention of dementia.</p>
<p style="text-indent:-2em;margin-left:2em;">The WHIMS estrogen plus progestin ancillary study of the WHI reported an increased risk of developing probable dementia in postmenopausal women ≥65 years of age during 4 years of treatment with daily CE (0.625 mg) combined with MPA (2.5 mg), relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. Do not use estrogen plus progestin therapy for the prevention of dementia.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Risks vs benefits:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Only daily oral CEs (0.625 mg) and daily oral CE (0.625 mg) and MPA (2.5 mg) were studied in the estrogen-alone and estrogen plus progestin substudies of the WHI, respectively. Therefore, the relevance of the WHI findings regarding the adverse cardiovascular events and dementia to lower CE doses, other routes of administration, or other estrogen-alone products is not known. Likewise, the relevance of the WHI findings regarding the adverse cardiovascular events, dementia, and breast cancer to lower CE plus other MPA doses, other routes of administration, or other estrogen plus progestin products is not known. Without such data, it is not possible to definitively exclude these risks or determine the extent of the risks for other products. Discuss with your patient the benefits and risks of estrogen-alone or estrogen plus progestin therapy, taking into account her individual risk profile. Prescribe estrogens with or without progestins at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F1884104"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Angeliq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868705"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Angeliq</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F1884108"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Estrogen and Progestin Combination</li></ul></div>
<div class="block doa drugH1Div" id="F1891115"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79865ee-c341-481c-9766-0202b4671186">Vasomotor symptoms associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause:</b>
<b> Note: </b>For use in symptomatic patients who are &lt;60 years of age or within 10 years of menopause who do not have contraindications to hormone therapy (eg, breast cancer) (NAMS 2022). Nonoral estrogen preparations are preferred in patients with hypertriglyceridemia, risk factors for venous thromboembolic disease, active gallbladder disease, and/or migraine headache with aura (Martin 2022a; Renoux 2010). Combination products are only indicated for patients with a uterus; the progestogen (ie, a natural progesterone or synthetic progestin) component prevents estrogen therapy-associated endometrial hyperplasia. Use of a combination product offers less dosing flexibility for initiating and tapering estrogen compared to separate estrogen and progestogen products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Oral:</b> Drospirenone 0.25 mg/estradiol 0.5 mg <b>or </b>drospirenone 0.5 mg/estradiol 1 mg per tablet: 1 tablet daily. <b>Note:</b> Initiate at the lowest dose and increase after ~4 weeks as needed to relieve symptoms (Martin 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy:</b> Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer and with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3679489c-0513-47c2-abaf-018b39b0ff61">Vulvar and vaginal atrophy associated with menopause</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause: Oral:</b> Drospirenone 0.5 mg/estradiol 1 mg per tablet: One tablet daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990199"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50987331"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F1891116"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Duration of use is not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F1884117"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia (6% to 18%), genital bleeding (3% to 14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Emotional lability (1%), migraine (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≤4% to 7%), gastrointestinal pain (≤4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cervical polyp (≤1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Cerebral infarction, cerebrovascular accident, embolism, hypersensitivity reaction, malignant neoplasm of breast, myocardial infarction, pulmonary vascular occlusion, pruritus, skin rash, thromboembolism, urticaria, venous obstruction (peripheral deep vein)</p></div>
<div class="block coi drugH1Div" id="F1884113"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Anaphylactic reaction, angioedema, or hypersensitivity to drospirenone, estradiol, or any component of the formulation; undiagnosed abnormal genital bleeding; deep vein thrombosis or pulmonary embolism (current or history of); active or history of arterial thromboembolic disease (eg, stroke, myocardial infarction); breast cancer (known, suspected, or history of); estrogen-dependent tumor (known or suspected); hepatic impairment or disease; renal impairment; adrenal insufficiency; known protein C, protein S, antithrombin deficiency or other known thrombophilic disorders.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Progestin-dependent malignant neoplasia (current or history of); benign or malignant liver tumors (current or history of); endometrial hyperplasia; severe hypertriglyceridemia; classic migraine; partial or complete loss of vision due to ophthalmic vascular disease; pregnancy (confirmed or suspected); breastfeeding.</p></div>
<div class="block war drugH1Div" id="F1884114"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Based on data from the Women’s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal patients using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA). Observational studies noted this risk declines once therapy is discontinued. The WHI study did not observe an increased risk of invasive breast cancer in patients with a hysterectomy using CE alone. The risk of breast cancer in patients who are postmenopausal receiving hormone therapy may depend upon type of estrogen and/or progestogen, dose, timing of therapy initiation, duration of therapy, route of administration, and individual patient characteristics (AACE/ACE [Cobin 2017]; NAMS 2022). Hormone therapy may be considered for patients who have entered menopause following an oophorectomy if the patient does not have a personal history of breast cancer; individualize treatment for menopausal symptoms (SGO/ASRM [Chen 2019]). Hormone therapy may be associated with increased breast density (NAMS 2022); an increase in abnormal mammogram findings requiring further evaluation has been reported with estrogen alone or in combination with progestogen therapy. Estrogen use may lead to severe hypercalcemia in patients with breast cancer and bone metastases; discontinue estrogen if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Do not use estrogens with or without progestogen to prevent dementia. In the Women’s Health Initiative Memory Study (WHIMS), an increased incidence of probable dementia was observed in patients ≥65 years of age taking CE alone or in combination with MPA. Because the WHIMS was conducted in patients ≥65 years of age, it is unknown if these findings apply to younger patients who are postmenopausal. However, hormone therapy is not recommended at any age to prevent or treat cognitive decline or dementia (AACE [Goodman 2011]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometrial cancer: The use of unopposed estrogen in patients with a uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Perform adequate diagnostic measures, including endometrial sampling if indicated to rule out malignancy in postmenopausal patients with undiagnosed abnormal vaginal bleeding. There is no evidence that the use of natural estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses. The risk of endometrial cancer appears to be dose and duration dependent, greatest with use ≥5 years, and may persist following discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Endometriosis: Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestogen in patients with residual endometriosis posthysterectomy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Drospirenone has antimineralocorticoid activity that may lead to hyperkalemia. Use caution with medications that may increase serum potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyponatremia: Drospirenone may increase the possibility of hyponatremia in high risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased in patients with preexisting hypertriglyceridemia; discontinue if pancreatitis occurs. Use with caution in patients with familial defects of lipoprotein metabolism.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ovarian cancer: Available information related to the use of menopausal estrogen or estrogen/progestogen therapy and risk of ovarian cancer is inconsistent. If an association is present, the absolute risk is likely rare and may be influenced by duration of therapy (AACE [Goodman 2011]; ES [Stuenkel 2015]; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Retinal vascular thrombosis: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Use caution in patients with asthma; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Do not use estrogens with or without progestogen to prevent cardiovascular disease. The WHI studies reported an increased risk of deep vein thrombosis (DVT) and stroke with CEs, and an increased risk of DVT, stroke, pulmonary emboli (PE), and myocardial infarction (MI) has been reported with CEs with MPA in patients who are postmenopausal 50 to 79 years of age. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, systemic lupus erythematosus (SLE), obesity, tobacco use, and/or history of venous thromboembolism (VTE). Manage risk factors appropriately; discontinue use immediately if adverse cardiovascular events occur or are suspected. Due to possible lower risk of thrombotic events, transdermal administration may be preferred for treating vasomotor symptoms of menopause in patients with risk factors for cardiovascular disease (ACOG 556 2013; AACE/ACE [Cobin 2017]; ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Chorea minor: Use caution with chorea minor; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: May impair glucose tolerance; use caution in patients with diabetes mellitus. Prior to therapy, consider age, cardiovascular and metabolic risk factors in patients previously diagnosed with diabetes (AACE/ACE [Cobin 2017]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Epilepsy: Use caution with epilepsy; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gallbladder disease: Use of postmenopausal estrogen may be associated with an increased risk of gallbladder disease requiring surgery.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic dysfunction: Estrogens are poorly metabolized in patients with hepatic dysfunction. Use caution with a history of cholestatic jaundice associated with prior estrogen use or pregnancy. Discontinue if jaundice develops or if acute or chronic hepatic disturbances occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic hemangiomas: Use with caution in patients with hepatic hemangiomas; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hereditary angioedema: Exogenous estrogens may exacerbate angioedema symptoms in patients with hereditary angioedema.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoparathyroidism: Use caution in patients with hypoparathyroidism; estrogen-induced hypocalcemia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use caution with migraine; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Otosclerosis: Use caution with otosclerosis; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• SLE: Use with caution in patients with SLE; may exacerbate disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Whenever possible, discontinue estrogens at least 4 to 6 weeks prior to elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Duration of use: Not clearly established; continued use may be appropriate in patients ≥60 years of age or &gt;10 years after menopause with a low risk of cardiovascular disease and breast cancer with persistent vasomotor symptoms after attempted taper/discontinuation of estrogen and trial of alternative therapies. Evaluate routinely for comorbidities and appropriateness of lower doses, nonoral routes of administration (preferred in patients ≥60 years of age), choice of progestogen, and discontinuation of therapy (NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Genitourinary syndrome of menopause (GSM): Low-dose vaginal estrogen is preferred over systemic therapy for GSM in the absence of vasomotor symptoms due to increased efficacy and decreased systemic effects (eg, cardiovascular effects, cancer risk) (Crandall 2018; NAMS 2013; NAMS 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Risks vs benefits: When used for the relief of menopausal symptoms or increased risk of bone fracture/loss, the benefit-risk of hormone therapy is most favorable if started in patients who have no contraindications to therapy, are &lt;60 years of age, within 10 years of menopause onset, have a favorable lipid profile, and do not have the factor V Leiden genotype or metabolic syndrome. Consider cardiovascular disease risk factors for when evaluating therapy and route of administration (AACE/ACE [Cobin 2017]; NAMS 2022). Use for the shortest duration possible at the lowest effective dose consistent with treatment goals and risks for the individual patient. Reevaluate patients as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women’s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in patients who are postmenopausal. Other combinations and dosage forms of estrogens and progestogens were not studied. Assume outcomes reported from clinical trials using CE with or without MPA to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.</p></div>
<div class="block foc drugH1Div" id="F1891120"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Angeliq: Drospirenone 0.5 mg and estradiol 1 mg, Drospirenone 0.25 mg and estradiol 0.5 mg</p></div>
<div class="block geq drugH1Div" id="F1884106"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F5164292"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Angeliq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25-0.5 mg (per each): $7.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5-1 mg (per each): $7.98</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868706"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Angeliq: 1-1 MG</p></div>
<div class="block adm drugH1Div" id="F14271118"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Swallow tablets whole with some liquid with or without food and take at the same time each day. Bleeding may occur if several doses are missed. Start therapy at any time in patients who are not taking estrogen or who are changing from a continuous combination product. Complete the current cycle before switching to this product in patients who are switching from sequential or cyclic hormone therapy. Take a forgotten dose as soon as possible. Do not take the missed tablet if more than 24 hours have passed.</p></div>
<div class="block hazard drugH1Div" id="F49104469"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]). </p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>
<div class="block use drugH1Div" id="F1884109"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasomotor symptoms associated with menopause:</b> Treatment of moderate to severe vasomotor symptoms associated with menopause in patients with a uterus.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Vulvar and vaginal atrophy associated with menopause:</b> Treatment of moderate to severe vulvar and vaginal atrophy due to menopause in patients with a uterus.</p>
<p style="text-indent:-2em;margin-left:4em;">Limitations of use: When used solely for the treatment of vulvar and vaginal atrophy, consider topical vaginal products.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>The International Society for the Study of Women’s Sexual Health and The North American Menopause Society have endorsed the term genitourinary syndrome of menopause (GSM) as new terminology for vulvovaginal atrophy. The term GSM encompasses all genital and urinary signs and symptoms associated with a loss of estrogen due to menopause (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25160739']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25160739'])">Ref</a></span>).</p></div>
<div class="block mst drugH1Div" id="F50169535"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F1884122"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP1A2 (weak)</p></div>
<div class="block dri drugH1Div" id="F1884121"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Estrogen Derivatives may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: Drospirenone-Containing Products may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: Drospirenone-Containing Products may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Drospirenone-Containing Products may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthrax Immune Globulin (Human): Estrogen Derivatives may enhance the thrombogenic effect of Anthrax Immune Globulin (Human). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Estrogen Derivatives may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Estrogen Derivatives may enhance the adverse/toxic effect of Chlorprothixene. Estrogen Derivatives may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Estrogen Derivatives may diminish the diagnostic effect of Cosyntropin.  Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: Estrogen Derivatives may enhance the hepatotoxic effect of Dantrolene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dehydroepiandrosterone: May enhance the adverse/toxic effect of Estrogen Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: Estrogen Derivatives may diminish the therapeutic effect of Exemestane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fezolinetant: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Fezolinetant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Growth Hormone Analogs: Estrogen Derivatives may diminish the therapeutic effect of Growth Hormone Analogs.  Management: Initiate somapacitan at 2 mg once weekly in patients receiving oral estrogens. Monitor for reduced efficacy of growth hormone analogs; increased doses may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hemin: Estrogen Derivatives may diminish the therapeutic effect of Hemin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Drospirenone-Containing Products may enhance the hyperkalemic effect of Heparin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): Estrogen Derivatives may increase the serum concentration of Hydrocortisone (Systemic). Estrogen Derivatives may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulin: Estrogen Derivatives may enhance the thrombogenic effect of Immune Globulin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indium 111 Capromab Pendetide: Estrogen Derivatives may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">LamoTRIgine: Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: Estrogen Derivatives may increase the serum concentration of Melatonin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Estrogen Derivatives may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking estrogen derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Estrogen Derivatives may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Drospirenone-Containing Products may enhance the hyperkalemic effect of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): May enhance the thrombogenic effect of Estrogen Derivatives. Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pomalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: Drospirenone-Containing Products may enhance the hyperkalemic effect of Potassium Salts. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Drospirenone-Containing Products may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Estrogen Derivatives. Protease Inhibitors may increase the serum concentration of Estrogen Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raloxifene: Estrogen Derivatives may enhance the adverse/toxic effect of Raloxifene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Estrogen Derivatives may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Estrogen Derivatives may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Estrogen Derivatives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine.  Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Estrogen Derivatives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F1884123"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Routine use of ethanol increases estrogen level and risk of breast cancer. Management: Avoid ethanol</p></div>
<div class="block pri drugH1Div" id="F1884110"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">This combination product is not indicated for use prior to menopause.</p></div>
<div class="block brc drugH1Div" id="F1884112"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone and estrogens are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Following administration of an oral contraceptive agent containing drospirenone, ~0.02% of the dose was detected in breast milk, resulting in a maximum of ~3 mcg/day drospirenone to the infant. Estrogens may decrease the quality and quantity of breast milk.</p></div>
<div class="block mop drugH1Div" id="F1891119"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to therapy, baseline risk for breast cancer and CVD. During therapy, age-appropriate breast and pelvic exams; blood pressure; unscheduled bleeding lasting &gt;6 months for endometrial pathology (sooner in patients who are obese, diabetic, or have a history of endometrial cancer); serum triglycerides (2 weeks after starting therapy in patients with baseline level &gt;200 mg/dL); TSH (6 to 12 weeks after starting oral therapy in patients taking thyroid replacement). Efficacy beginning 1 to 3 months after starting therapy, then every 6 to 12 months as appropriate. Evaluate duration of treatment at least annually (ES [Stuenkel 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">Serum potassium during the first month of therapy in patients at risk for hyperkalemia and who are on chronic strong CYP3A4 inhibitors</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Monitoring of FSH and serum estradiol is not useful when managing vasomotor symptoms or genitourinary symptoms of menopause.</p></div>
<div class="block pha drugH1Div" id="F1891108"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone is a synthetic progestin and spironolactone analog with antimineralocorticoid and antiandrogenic activity. Counteracts estrogen effects causing endometrial thinning.</p>
<p style="text-indent:-2em;margin-left:2em;">Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the principal intracellular human estrogen and is more potent than estrone and estriol at the receptor level; it is the primary estrogen secreted prior to menopause. Following menopause, estrone and estrone sulfate are more highly produced. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system; estrogen replacement reduces elevated levels of these hormones in patients who are postmenopausal.</p></div>
<div class="block phk drugH1Div" id="F1884126"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Drospirenone: 4.2 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding:</p>
<p style="text-indent:-2em;margin-left:4em;">Drospirenone: 97%; does not bind to sex hormone binding globulin or corticosteroid binding globulin</p>
<p style="text-indent:-2em;margin-left:4em;">Estradiol: 37% bound to sex hormone binding globulin; 61% bound to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic</p>
<p style="text-indent:-2em;margin-left:4em;">Drospirenone forms two metabolites (inactive)</p>
<p style="text-indent:-2em;margin-left:4em;">Estradiol: Converted to estrone and estriol; also undergoes enterohepatic recirculation; estrone sulfite is the main metabolite in patients who are postmenopausal.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Drospirenone: 76% to 85%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Drospirenone: ~36-42 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Drospirenone: 1 hour; Estradiol: ~2 hours (range: 0.3-10 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Drospirenone: Urine and feces; Estradiol: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F4301368"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Eos | Equifem MD</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rozy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Klimedix</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Ceci</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Altesse | Estredox | Gadofem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Clinomat | Jex | Marcelle</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Paosonelle</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Klimedix</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bilive | Clinomat | Gadofem | Postelle</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Clinomat | Gadofem | Marcelle</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Paosonelle</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Klimedix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Paosonelle</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Clinomat | Gadofem</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Klimedix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Clinomat</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Angeliq micro</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Angemin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Angeliq | Equifem | Gadofem</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clinomat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Angeliq</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-23635705">
<a name="23635705"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: Postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. <i>Obstet Gynecol</i>. 2013;121:887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/23635705/pubmed" id="23635705" target="_blank">23635705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812486">
<a name="23812486"></a>American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 565: Hormone therapy and heart disease. <i>Obstet Gynecol</i>. 2013;121:1407-1410.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/23812486/pubmed" id="23812486" target="_blank">23812486</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15082697">
<a name="15082697"></a>Anderson GL, Limacher M, Assaf AR, et al, "Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial." <i>JAMA</i>, 2004, 291(14):1701-1712.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/15082697/pubmed" id="15082697" target="_blank">15082697</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Angeliq (drospirenone and estradiol) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals; October 2023.</div>
</li>
<li>
<div class="reference">
                  Angeliq (drospirenone and estradiol) [product monograph]. Mississauga, Ontario, Canada: Bayer Inc; February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28703650">
<a name="28703650"></a>Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) position statement on menopause-2017 update. <i>Endocr Pract</i>. 2017;23(7):869-880. doi: 10.4158/EP171828.PS.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/28703650/pubmed" id="28703650" target="_blank">28703650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28816933">
<a name="28816933"></a>Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i>. 2018;25(1):11-20. doi: 10.1097/GME.0000000000000956.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/28816933/pubmed" id="28816933" target="_blank">28816933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22193047">
<a name="22193047"></a>Goodman NF, Cobin RH, Ginzburg SB, Katz IA, Woode DE; American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. <i>Endocr Pract</i>. 2011;17)(suppl 6):1-25. doi:10.4158/ep.17.s6.1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/22193047/pubmed" id="22193047" target="_blank">22193047</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16476878">
<a name="16476878"></a>Hsia J, Langer RD, Manson JE, et al, "Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative," <i>Arch Intern Med</i>, 2006, 166(3):357-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/16476878/pubmed" id="16476878" target="_blank">16476878</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35797481">
<a name="35797481"></a>North American Menopause Society (NAMS). The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of the North American Menopause Society. <i>Menopause</i>. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/35797481/pubmed" id="35797481" target="_blank">35797481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32852449">
<a name="32852449"></a>North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. <i>Menopause</i>. 2020;27(9):976-992. doi:10.1097/GME.0000000000001609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/32852449/pubmed" id="32852449" target="_blank">32852449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25160739">
<a name="25160739"></a>Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. <i>Menopause</i>. 2014; 21(10):1063-1068.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/25160739/pubmed" id="25160739" target="_blank">25160739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20230416">
<a name="20230416"></a>Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. <i>J Thromb Haemost.</i> 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/20230416/pubmed" id="20230416" target="_blank">20230416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12117397">
<a name="12117397"></a>Rossouw JE, Anderson GL, Prentice RL, et al, “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,”<i>JAMA</i>, 2002, 288(3):321-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/12117397/pubmed" id="12117397" target="_blank">12117397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771112">
<a name="12771112"></a>Shumaker SA, Legault C, Rapp SR, et al, “Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,” <i>JAMA</i>, 2003, 289(20):2651-2662.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/12771112/pubmed" id="12771112" target="_blank">12771112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21538049">
<a name="21538049"></a>Sitruk-Ware R and Nath A, "Metabolic Effects of Contraceptive Steroids," <i>Rev Endocr Metab Disord</i>, 2011, 12(2):63-75.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/21538049/pubmed" id="21538049" target="_blank">21538049</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26444994">
<a name="26444994"></a>Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015; 100(11):3975-4011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/26444994/pubmed" id="26444994" target="_blank">26444994</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference">
                  US Food and Drug Administration, Department of Health and Human Services, “WHIMS Study on Estrogen/Progestin,” May 27, 2003. Available at <a href="http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm" target="_blank">http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm135318.htm</a>
</div>
</li>
<li>
<div class="reference">
                  Vestura (drospirenone and ethinyl estradiol) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12771114">
<a name="12771114"></a>Wassertheil-Smoller S, Hendrix S, Limacher M, et al, “Effect of Estrogen Plus Progestin on Stroke in Postmenopausal Women: The Women's Health Initiative: A Randomized Trial,” <i>JAMA</i>, 2003, 289:2673-2684.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/drospirenone-and-estradiol-drug-information/abstract-text/12771114/pubmed" id="12771114" target="_blank">12771114</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8802 Version 298.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
